The finding that deletion of JNK1 prevented the impairment of insulin secretion and β cell survival induced by proinflammatory cytokines (2, 5, 6) suggests that targeting JNK1 and JNK2 in β cells could be a new therapeutic approach for diabetes (7–9). Here, INS is linked to diabetes mellitus.